MedTrace Logo

Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

NCT03437668 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2024-10-08

Study results available
· View outcomes & findings →

Summary

To determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total score) in persons with schizophrenia. A secondary aim is to determine whether WSE reduces measures of positive and negative symptoms (PANSS subscales) and stress scores on the Perceived Stress Scale (PSS).

Conditions

Interventions

DRUG

WSE

WSE tablets

DRUG

Placebo Oral Tablet

Placebo tablet

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • University of Maryland

    collaborator OTHER

  • Chengappa, K.N. Roy, MD

    lead OTHER

Principal Investigators

  • Stephen Marder, MD · Semel Inst at UCLA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2023-06-12
Completion
2023-06-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03437668 on ClinicalTrials.gov